Approximately 300,000 women are diagnosed with ovarian cancer every year. Five year survival rates are poor, at less than 50% and have remained static for several decades. One of the reasons for this poor survival is the advanced stage presentation of many patients. There is a significant unmet need to improve early detection of ovarian cancer to improve outcome for patients. Research and development of EpiCapture-ovarian is at an early stage underway at University College Dublin.
Research supported by: